Related Experiment Videos
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma
Urology
|November 1, 1986
Abstract:
This prospective randomized study in nonhormonally responsive adenocarcinoma of the prostate shows that response rates to melphalan vs cyclophosphamide groups were virtually identical.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Rotator cuff outcomes and mental health indices: Correlation or causation?
Shoulder & elbow·2023
Interstitial Granulomatous Drug Reaction to Ustekinumab.
Case reports in dermatological medicine·2022
Disseminated protothecosis with central nervous system involvement in a dog in New Zealand.
New Zealand veterinary journal·2022
A Markov model cost threshold analysis of potential hepatitis B virus cure regimens.
Clinical and translational gastroenterology·2026
Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Is there a role for palliative care in CAR T-cell therapy?
Current opinion in supportive and palliative care·2026